Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts.

Adisetiyo H, Liang M, Liao CP, Jeong JH, Cohen MB, Roy-Burman P, Frenkel B.

J Cell Physiol. 2014 Sep;229(9):1170-6. doi: 10.1002/jcp.24546.

2.

Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.

Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K, Zhang D, Liu B, Jeter C, Calhoun-Davis T, Lin K, Lu Y, Chao HP, Shen J, Tang DG.

Clin Cancer Res. 2016 Sep 1;22(17):4505-16. doi: 10.1158/1078-0432.CCR-15-2956. Epub 2016 Apr 8.

3.

CAF-secreted annexin A1 induces prostate cancer cells to gain stem cell-like features.

Geary LA, Nash KA, Adisetiyo H, Liang M, Liao CP, Jeong JH, Zandi E, Roy-Burman P.

Mol Cancer Res. 2014 Apr;12(4):607-21. doi: 10.1158/1541-7786.MCR-13-0469. Epub 2014 Jan 24.

4.

A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.

Sackmann Sala L, Boutillon F, Menara G, De Goyon-Pélard A, Leprévost M, Codzamanian J, Lister N, Pencik J, Clark A, Cagnard N, Bole-Feysot C, Moriggl R, Risbridger GP, Taylor RA, Kenner L, Guidotti JE, Goffin V.

J Pathol. 2017 Sep;243(1):51-64. doi: 10.1002/path.4924. Epub 2017 Jul 28.

PMID:
28603917
5.

Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.

Pham LK, Liang M, Adisetiyo HA, Liao CP, Cohen MB, Tahara SM, Frenkel B, Kasahara N, Roy-Burman P.

Endocr Relat Cancer. 2013 Nov 4;20(6):861-74. doi: 10.1530/ERC-13-0100. Print 2013 Dec.

6.

Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells.

Liao CP, Adisetiyo H, Liang M, Roy-Burman P.

Cancer Res. 2010 Sep 15;70(18):7294-303. doi: 10.1158/0008-5472.CAN-09-3982. Epub 2010 Aug 31.

7.

Cancer stem cells and microenvironment in prostate cancer progression.

Liao CP, Adisetiyo H, Liang M, Roy-Burman P.

Horm Cancer. 2010 Dec;1(6):297-305. doi: 10.1007/s12672-010-0051-5.

PMID:
21761361
8.

Upregulation of FAM84B during prostate cancer progression.

Wong N, Gu Y, Kapoor A, Lin X, Ojo D, Wei F, Yan J, de Melo J, Major P, Wood G, Aziz T, Cutz JC, Bonert M, Patterson AJ, Tang D.

Oncotarget. 2017 Mar 21;8(12):19218-19235. doi: 10.18632/oncotarget.15168.

9.

Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells.

Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B, Fazli L, Gleave M, Witte ON, Garraway IP, Wu H.

PLoS One. 2012;7(8):e42564. doi: 10.1371/journal.pone.0042564. Epub 2012 Aug 3.

10.

HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.

Ruscetti M, Dadashian EL, Guo W, Quach B, Mulholland DJ, Park JW, Tran LM, Kobayashi N, Bianchi-Frias D, Xing Y, Nelson PS, Wu H.

Oncogene. 2016 Jul 21;35(29):3781-95. doi: 10.1038/onc.2015.444. Epub 2015 Dec 7.

11.

A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance.

Jeong JH, Park SJ, Dickinson SI, Luo JL.

Mol Cell. 2017 Jan 5;65(1):154-167. doi: 10.1016/j.molcel.2016.11.034. Epub 2016 Dec 29.

12.

Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist.

Ruan D, He J, Li CF, Lee HJ, Liu J, Lin HK, Chan CH.

Oncogene. 2017 Jul 27;36(30):4299-4310. doi: 10.1038/onc.2017.64. Epub 2017 Mar 27.

13.

Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.

Patki M, Huang Y, Ratnam M.

Biochem Biophys Res Commun. 2016 Jul 22;476(2):69-74. doi: 10.1016/j.bbrc.2016.05.058. Epub 2016 May 12.

14.

NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.

Yu C, Wu G, Li R, Gao L, Yang F, Zhao Y, Zhang J, Zhang R, Zhang J, Yao L, Yuan J, Li X.

Cancer Biol Ther. 2015;16(2):287-96. doi: 10.1080/15384047.2014.1002348.

15.

Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.

Lubik AA, Nouri M, Truong S, Ghaffari M, Adomat HH, Corey E, Cox ME, Li N, Guns ES, Yenki P, Pham S, Buttyan R.

Int J Cancer. 2017 Jan 15;140(2):358-369. doi: 10.1002/ijc.30450. Epub 2016 Oct 20.

16.

Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.

Hu X, Garcia C, Fazli L, Gleave M, Vitek MP, Jansen M, Christensen D, Mulholland DJ.

Sci Rep. 2015 Nov 13;5:15182. doi: 10.1038/srep15182.

17.

The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.

Tien JC, Liu Z, Liao L, Wang F, Xu Y, Wu YL, Zhou N, Ittmann M, Xu J.

Cancer Res. 2013 Jul 1;73(13):3997-4008. doi: 10.1158/0008-5472.CAN-12-3929. Epub 2013 May 6.

18.

Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity.

Abou-Kheir W, Hynes PG, Martin P, Yin JJ, Liu YN, Seng V, Lake R, Spurrier J, Kelly K.

PLoS One. 2011;6(10):e26112. doi: 10.1371/journal.pone.0026112. Epub 2011 Oct 11.

19.

Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.

De Velasco MA, Tanaka M, Yamamoto Y, Hatanaka Y, Koike H, Nishio K, Yoshikawa K, Uemura H.

Carcinogenesis. 2014 Sep;35(9):2142-53. doi: 10.1093/carcin/bgu143. Epub 2014 Jul 1.

20.

Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.

Xie X, Kong Y, Tang H, Yang L, Hsu JL, Hung MC.

Mol Cancer Ther. 2014 Jul;13(7):1813-25. doi: 10.1158/1535-7163.MCT-13-1004. Epub 2014 Apr 30.

Supplemental Content

Support Center